Pharmaceutical composition for controlled release of treprostinil
US11833125B2 · kind B2 · utility
0Cited by
2References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 27, 2021 |
| Grant date | Dec 5, 2023 |
| Priority date | — |
| Expiry date | May 24, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0078
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are pharmaceutical compositions containing (a) at least one liposome includes at least one vesicle-forming phospholipid; and (b) treprostinil encapsulated within the liposome. The ratio of treprostinil to phospholipid is equal to or higher than 0.035 and provides a controlled release of treprostinil. Also provided is the use of the pharmaceutical compositions to treat respiratory diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.